| Structural determinants of HERG channel block by clofilium and ibutilide M Perry, MJ de Groot, R Helliwell, D Leishman, M Tristani-Firouzi, ... Molecular pharmacology 66 (2), 240-249, 2004 | 196 | 2004 |
| Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. R Webster, D Leishman, D Walker Current opinion in drug discovery & development 5 (1), 116-126, 2002 | 149 | 2002 |
| Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin AJ Alexandrou, RS Duncan, A Sullivan, JC Hancox, DJ Leishman, ... British journal of pharmacology 147 (8), 905-916, 2006 | 135 | 2006 |
| Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics HM Vargas, AS Bass, A Breidenbach, HS Feldman, GA Gintant, ... Journal of pharmacological and toxicological methods 58 (2), 72-76, 2008 | 107 | 2008 |
| Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 C: Cisapride versus dofetilide JT Milnes, HJ Witchel, JL Leaney, DJ Leishman, JC Hancox Journal of pharmacological and toxicological methods 61 (2), 178-191, 2010 | 106 | 2010 |
| Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs M Perry, PJ Stansfeld, J Leaney, C Wood, MJ De Groot, D Leishman, ... Molecular pharmacology 69 (2), 509-519, 2006 | 104 | 2006 |
| Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society DJ Leishman, TW Beck, N Dybdal, DJ Gallacher, BD Guth, M Holbrook, ... Journal of Pharmacological and Toxicological Methods 65 (3), 93-101, 2012 | 98 | 2012 |
| Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc DA Price, D Armour, M de Groot, D Leishman, C Napier, M Perros, ... Bioorganic & medicinal chemistry letters 16 (17), 4633-4637, 2006 | 92 | 2006 |
| A framework to assess the translation of safety pharmacology data to humans JP Valentin, R Bialecki, L Ewart, T Hammond, D Leishmann, S Lindgren, ... Journal of Pharmacological and Toxicological Methods 60 (2), 152-158, 2009 | 89 | 2009 |
| A pharmacokinetic‐pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether‐a‐go‐go‐related gene current inhibition data DM Jonker, LA Kenna, D Leishman, R Wallis, PA Milligan, EN Jonsson Clinical pharmacology & therapeutics 77 (6), 572-582, 2005 | 82 | 2005 |
| General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy Z Li, GR Mirams, T Yoshinaga, BJ Ridder, X Han, JE Chen, ... Clinical Pharmacology & Therapeutics 107 (1), 102-111, 2020 | 80 | 2020 |
| The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative L Ewart, M Aylott, M Deurinck, M Engwall, DJ Gallacher, H Geys, P Jarvis, ... Toxicological Sciences 142 (2), 427-435, 2014 | 77 | 2014 |
| Identification of a low molecular mass (14.2 kDa) α-tocopherol-binding protein in the cytosol of rat liver and heart AK Duttaroy, DJ Leishman, MJ Gordon, FM Campbell, GG Duthie Biochemical and biophysical research communications 196 (3), 1108-1112, 1993 | 76 | 1993 |
| Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research … B Darpo, C Garnett, CT Benson, J Keirns, D Leishman, M Malik, ... American heart journal 168 (3), 262-272, 2014 | 73 | 2014 |
| Time for a fully integrated nonclinical–clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective HM Vargas, MG Rolf, TA Wisialowski, W Achanzar, A Bahinski, A Bass, ... Clinical Pharmacology & Therapeutics 109 (2), 310-318, 2021 | 72 | 2021 |
| Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin RS Duncan, MJ McPate, JM Ridley, Z Gao, AF James, DJ Leishman, ... Biochemical pharmacology 74 (3), 425-437, 2007 | 70 | 2007 |
| Developing in vitro assays to transform gastrointestinal safety assessment: potential for microphysiological systems MF Peters, AL Choy, C Pin, DJ Leishman, A Moisan, L Ewart, ... Lab on a Chip 20 (7), 1177-1190, 2020 | 65 | 2020 |
| The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment AA Fossa, MJ DePasquale, DL Raunig, MJ Avery, DJ Leishman Journal of Pharmacology and Experimental Therapeutics 302 (2), 828-833, 2002 | 63 | 2002 |
| hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656 JT Milnes, HJ Witchel, JL Leaney, DJ Leishman, JC Hancox Biochemical and biophysical research communications 351 (1), 273-280, 2006 | 58 | 2006 |
| Purification and partial characterisation of an α-tocopherol-binding protein from rabbit heart cytosol AK Dutta-Roy, MJ Gordon, DJ Leishman, BJ Paterson, GG Duthie, ... Cellular Fatty Acid-Binding Proteins II: Proceedings of the 2nd …, 1993 | 55 | 1993 |
